What is SpliSense?
Based in Jerusalem, Israel, SpliSense was founded in 2016 with a mission to develop transformative mRNA-altering treatments. The company is focused on tackling genetic pulmonary diseases, a complex area of medicine with significant unmet patient needs. By leveraging advanced mRNA technology, SpliSense aims to create novel therapeutic solutions that can fundamentally alter the course of these debilitating conditions. The company's strategic focus on genetic respiratory diseases positions it within a specialized and rapidly evolving segment of the biopharmaceutical industry.
How much funding has SpliSense raised?
SpliSense has raised a total of $28.5M across 1 funding round:
Series B
$28.5M
Series B (2021): $28.5M with participation from Cystic Fibrosis Foundation, Integra Holdings, OrbiMed, Israel Biotech Fund, and Biotel Limited
Key Investors in SpliSense
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is a non-profit organization dedicated to finding cures for cystic fibrosis and ensuring those living with the condition can lead long, productive lives. Their investment in SpliSense highlights a commitment to advancing treatments for genetic pulmonary diseases.
Integra Holdings
Integra Holdings acts as an investment gateway for early-stage life science research from Hebrew University, focusing on innovations in Pharma Biotechnology, Medical Devices, Diagnostics, and AI. Their involvement suggests a strategic interest in novel therapeutic technologies.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and diagnostics. Their investment indicates a focus on promising healthcare innovations with significant market potential.
What's next for SpliSense?
The recent major strategic investment in SpliSense signals a pivotal phase for the company, likely enabling accelerated clinical development, expansion of its research and development capabilities, and potential progression towards later-stage trials. This infusion of capital is expected to fuel the company's efforts to bring its innovative mRNA-altering therapies to patients suffering from genetic pulmonary diseases. SpliSense's trajectory suggests a strong emphasis on scientific validation and strategic partnerships to navigate the complex path from discovery to market.
See full SpliSense company page
